INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com